Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 2/20 | 0.39 |
| ▸ | PARN | O95453 | 1/20 | 0.39 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14105484 | 0.71 | CYP11B2 (0.41) | GDACYP11B2SMN1; SMN2KDM4CADORA2B | |
| SCHEMBL16068380 | 0.67 | CYP11B2 (0.54) | GDACYP11B2SMN1; SMN2KDM4CADORA2B | |
| SCHEMBL15624418 | 0.65 | CYP11B2 (0.49) | GDACYP11B2SMN1; SMN2KDM4CADORA2B | |
| SCHEMBL15624462 | 0.64 | CYP11B2 (0.45) | GDACYP11B2SMN1; SMN2KDM4CADORA2B | |
| SCHEMBL30595217 | 0.63 | PARN (0.54) | CYP11B2SMN1; SMN2KDM4CADORA2BRXFP1 | |
| SCHEMBL22751731 | 0.61 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL9698769 | 0.61 | PTGS2 (0.61) | CYP11B2TNFCYP11B1GSK3BLMNA | |
| Hydantoin SCHEMBL4914979 | 0.61 | GSK3A (0.77) | SMN1; SMN2GSK3AGSK3BGAA | |
| SCHEMBL21186576 | 0.61 | GDA (0.43) | GDACYP11B2SMN1; SMN2KDM4CADORA2B | |
| SCHEMBL7459635 | 0.60 | BRD4 (0.62) | SMN1; SMN2ADORA2BRXFP1PNPPARN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2006-10-26 | — | — | US | disclosed |
| EP-1227103-B1 | Ring-expanded nucleosides and nucleotides | NABI (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2004-04-22 | — | — | US | disclosed |
| US-6677310-B1 | ANTICARCINOGENIC AGENTS; BACTERICIDES, FUNGICIDES, PARASITICIDES; VIRICIDES AGAINST HEPATITIS, EPSTEIN-BARR, CYTOMEGALO AND HUMAN IMMUNODEFICIENCY VIRUS | NABI | 2004-01-13 | — | — | US | disclosed |
| EP-0724587-B8 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-0724587-B1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0724587-A4 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0724587-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | Burns, Barry (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995009175-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | PNP, UMPS, ADA | GDA 53/4885CYP11B2 2629/4885SMN1; SMN2 2695/4885 |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | PNP, PAICS, UMPS | GDA 49/4885CYP11B2 2268/4885SMN1; SMN2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.